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shortcut though impairs the analysis in many different ways, limiting our full
understanding of the phenomenon being modelled and ultimately our ability to
accurately assess ‘value for money’ beyond the simple ‘average’. This paper ex-
plores the value of access to individual patient data for cost-effectiveness model-
ling, structuring the discussion of the topic around three interrelated questions.
First, what benefits can access to IPD bring to cost-effectiveness modelling? Sec-
ond, what are the challenges for the simultaneous statistically synthesis of AD plus
IPD to derive input parameters for a cost-effectiveness model? Third, what is the
value of access to IPD compared to AD for cost-effectiveness modelling? Using two
different case studies, the above questions will be addressed and discussed in the
context of the debate around CEA of individualised treatment decisions.
DISEASE-SPECIFIC STUDIES
GASTROINTESTINAL DISORDERS - Clinical Outcomes Studies
PGI1
THE EFFECTIVENESS AND TOLERABILITY OF COMBINED TREATMENT WITH
PEGINTERFERON ALPHA-2A OR ALPHA-2B AND RIBAVIRIN IN THE TREATMENT
OF PATIENTS WITH CHRONIC HEPATITIS C: RESULTS BASED ON THE
NATIONWIDE HEPATITIS REGISTRY IN JAPAN
Shimbo T, Miyaki K, Song Y, Masaki N, Study Group Developing Nationwide Database of
Hepatitis Japan
National Center for Global Health and Medicine, Shinjuku-ku, Tokyo, Japan
OBJECTIVES: When comparing combined therapy with peginterferon alpha-2a or
alpha-2b and ribavirin to treat chronic hepatitis C (CHC), the results of clinical
trials, observational studies, and meta-analyses have been inconsistent. Their ef-
fectiveness and tolerability were investigated using the nationwide database of
chronic hepatitis patients who received interferon therapy in Japan. METHODS:
The proportion with a sustained virologic response (SVR) and the dropout rate due
to adverse events (AEs) were compared between alpha-2a and alpha-2b. All pa-
tients also received ribavirin. Multivariate logistic regression was conducted with
adjustment for age, sex, platelet counts, ALT, viral load, genotype, and whether the
patient was treatment-naïve, which are associated with effectiveness and
tolerability. RESULTS: By December 2011, the database included 7820 patients. CHC
patients treated with either alpha-2a (n1737) or alpha-2b (n4495) were analyzed.
The mean (SD) age was 58.1 (10.4) years, and 3131 (50.2%) were female. In total, 2503
(41.0%) patients had a platelet count150x103, 2503 (40.5%) had ALT 60 IU/L, and
5765 (93.2%) had a high viral load. The numbers with genotype 1, 2, and 3 were 4291
(69.2%), 1838 (29.6%), and 76 (1.2%), respectively. Overall, 4434 (71.2%) patients were
treatment-naïve. SVR was achieved in 53.5% (95% CI: 51.1-55.9%) with alpha-2a and
61.6% (95% CI: 60.2-63.1%) with alpha-2b (p0.001). The dropout rate due to any AEs
was 10.3% (95%CI: 8.9-11.8%) and 9.3% (95%CI: 8.5-10.2%) for alpha-2a and alpha-2b,
respectively (p0.226). After adjustment for possible confounders, no differences
in effectiveness or tolerability were observed between the therapies, and the odds
ratio of alpha-2a for SVR was 0.97 (95% CI: 0.86-1.10), and its odds ratio for dropout
due to any AEs was 0.96 (95% CI: 0.79-1.17). There was no significant interaction of
genotype and therapy.CONCLUSIONS:Alpha-2a and alpha-2b in combination with
ribavirin showed comparable effectiveness and tolerability in clinical settings.
PGI2
INFLIXIMAB REDUCES THE RISK OF SURGICAL INTERVENTIONS AND
HOSPITALIZATION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
Costa J1, Alarcão J1, Caldeira D2, Borges M1, Vaz Carneiro A1
1Center for Evidence Based Medicine, Faculty of Medicine, University of Lisbon, Lisbon, Portugal,
2Laboratory of Clinical Pharmacology and Therapeutics, Faculty of Medicine, University of Lisbon,
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OBJECTIVES: In addition to the pharmacological efficacy of infliximab therapy in
inflammatory bowel disease (IBD), it is also important to evaluate its impact on
other health outcomes, particularly in the rate of surgical interventions and hos-
pitalizations, which have high economic burden and are believed to represent a
marker of IBD severity. We aimed to estimate the impact of infliximab in these
outcomes in patients with IBD.METHODS: Systematic review and meta-analysis of
experimental (clinical trials) and observational studies comparing infliximab with
any other control group in IBD. Studies were identified by searching Medline and
Cochrane from inception to April 2012. Search results and studies characteristics
were assessed independently. Subgroup analyses were done according to IBD type:
Crohn disease (CD) and ulcerative colitis (UC). Pooled estimates were performed
separately for clinical trials and observational studies. Odds ratios (OR) and 95%
confidence intervals (CI) were derived by random-effects meta-analysis. Heteroge-
neity was assessed with I2 test. RESULTS: Nine trials and 9 observational studies
were included. Infliximab significantly decreased risk of gastrointestinal surgery in
experimental studies (OR 0.36; 95%CI: 0.18-0.71), both in DC (OR 0.25; 95%CI: 0.10-
0.63) and UC (OR 0:55; 95%CI: 0.40-0.76). In absolute terms, there was a 9% reduction
in the rate of surgery (95%CI: 1-19%). Observational studies also showed a reduced
risk of surgery, which was significant in the case of CD (OR 0.42; 95% CI: 0.22 to 0.78).
Infliximab significantly reduced the risk of hospitalization, both in experimental
(OR 0.48; 95%CI: 0.34-0.66) and observational (OR 0:38; 95%CI: 0.24-0.58) studies,
with a decrease of 9% in hospitalization rate (95%CI: 5-14%). Mean duration of
hospitalization was shorten by 4.2 days (95%CI: 1.9-6.5) in infliximab treated
patients. CONCLUSIONS: Based on the best available evidence, infliximab therapy
is associated with a reduced risk of gastrointestinal surgery and hospitalization
rates in patients with IBD.
PGI3
TREATMENT OF CHRONIC HEPATITIS C GENOTYPE 1 IN POLAND – REAL-LIFE
DATA
Kaczor MP1, Pawlik D2, Wójcik R2, Rolka M2, Maniszewska-Weyher I3, Tronczynski K3
1Jagiellonian University Medical College, Kraków, Poland, 2Aestimo s.c., Kraków, Poland,
3Janssen-Cilag Polska, Warsaw, Poland
OBJECTIVES: To describe health outcomes, the course of treatment and the
demographic and clinical characteristics of HCV adult patients infected with
genotype 1 receiving interferon-alfaribavirin therapy in Poland. METHODS: A
retrospective analysis of anonymous data of patients treated in the HCV thera-
peutic programme of the National Health Fund was performed. Data was gath-
ered from three medical centres and included demographic and clinical char-
acteristics (sex, age, body weight, initial HCV RNA level, disease staging and
grading) as well as treatment course (first line/retreatment, posology, treatment
duration, outcomes and discontinuations). RESULTS: A total of 813 HCV geno-
type 1 adult patients’ records [586 treatment-naïve (N) and 227 treatment-expe-
rienced (E)] were included in the analysis. 55% were male (N: 53%, E: 60%), mean
age at the beginning of therapy was 48 (SD:13) years. Mean body weight was 68,0
(SD:11,8) kg in females and 82,4 (SD:12,3) kg in males. Mean initial HCV RNA was
5,9 (SD:0,8) log10IU/mL and 46% of patients had HCV RNA800 000 IU/mL. A total
of 85% records included data on disease staging (Sheuer 0-2: 67%; stage 3: 19%;
stage 4: 14%). 96% of patients received pegylated interferons (pegylated inter-
feron-alfa2a: 54%), 97% with ribavirin. A total of 15% of patients discontinued
therapy prematurely (N: 14%, E: 18%) after a mean of 6 months, and mean
treatment duration was 44 weeks for all patients. Overall SVR (sustained viral
response) was achieved in 42% of patients (N: 45%, E: 33%). Among treatment-
naïve patients not fully responding to therapy, 41% had relapse, 21% were par-
tial responders and 38% were null-responders. CONCLUSIONS: The real-life re-
sults of HCV genotype 1 treatment, with SVR rates below 50% in treatment naïve
patients, are unsatisfactory, especially when in Poland the prevalence of this
difficult-to-treat genotype is one of the most highest in Europe. Forthcoming
triple therapy with HCV protease inhibitors are promising and anticipated op-
tions for these patients.
PGI4
EVALUATION OF THE EFFICACY AND INCONTINENCE RATE OF BIOMATERIALS
IN COMPARISON TO CONSERVATIVE AND OTHER INTERVENTIONAL
THERAPIES IN TREATMENT OF PERIANAL FISTULA. A META-ANALYSIS
Mirfazaelian H1, Nikfar S2, Derakhshani S3, Abdollahi M1
1Tehran University of Medical Sciences, Tehran, Iran, 2Tehran University of Medical Sciences,
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OBJECTIVES: This meta-analysis of randomized controlled trials was conducted to
evaluate the efficacy and incontinence rate of biomaterials (fibrin glue and fibrin
plug) in comparison to conservative and other interventional therapy in the treat-
ment of perianal fistula. METHODS: PubMed, Embase, Scopus, Google Scholar, and
Web of Science were searched for clinical trial studies investigated the effects of
biomaterials in the treatment of fistul in-ano. Clinical response and incontinence
were the key outcomes of interest. Data were searched from the time period of 1966
through June 2012. RESULTS: Eight randomized placebo-controlled clinical trials
that met our criteria (six comparing biomaterial with conservative treatment and
two with other interventions) were included in the analysis. Pooling of data showed
biomaterials effectiveness in comparison to other interventions was non signifi-
cant with relative risk (RR) of 1.23 (95% CI of 0.31-4.84, P 0.77). The RR for bioma-
terials comparing with conservative was non significant (RR 0.73 with 95% CI 
0.31-0.89, P 0.096). The incontinence rate RR in biomaterials and intervention was
also non significant with RR of 0.35 (95% CI  0.05-2.28, P  0.27). CONCLUSIONS:
This meta-analysis demonstrates that the effectiveness of biomaterials and con-
servative treatment was not different. The biomaterials in comparison to other
interventional therapies did not show any difference in regard to effectiveness and
also incontinence rate.
PGI5
EFFECTIVENESS AND SAFETY OF ANTACIDS IN PREGNANT WOMEN SUFFERING
FROM GERD/HYPERACIDITY SYMPTOMS
Donde S
Pfizer India, Mumbai, India
OBJECTIVES: Symptoms of gastro-oesophageal reflux disease are estimated to
occur in 30-50% of pregnancies, with the incidence approaching 80% in some
populations. Indian studies have shown prevalence ranging upto 50 % . As with
many other conditions in pregnancy, medical therapy with pharmaceutical
agents is a concern, as the potential teratogenicity of medications is not well
known. Though prevalence numbers are high, many patients have mild and
infrequent symptoms, which often respond to lifestyle and dietary modifica-
tions. However, some patients report very severe symptoms of hyperacidity
affecting their Quality of Life which need treatment. The safety of H2 Receptor
antagonists and PPIs in pregnancy is not well established. Antacids could be a
good option as their systemic toxicity is low and safety profile is enhanced.
METHODS: Data has been collected from practicing gynaecologists in a hospital
located in Southern India . 50 female patients suffering from heartburn and/or
dyspepsia as symptoms of hyperacidity and GERD were treated with antacids
containing aluminium hydroxide, magnesium hydroxide and dimethicone. The
patients were prescribed antacids for atleast 7 days and the effectiveness and
safety profile of antacids was studied. The patients were followed up after one
week and the response along with adverse effects were documented. RESULTS:
The effectiveness was achieved in 85 % of women who took only antacids atleast
for 1 week. In 10 % of patients, Proton Pump Inhibitor was also added to achieve
the desired response. Apart from 2 cases of mild diarrhea, no other significant
side effects were noted. CONCLUSIONS: Antacids containing aluminium hy-
droxide , magnesium hydroxide and dimethicone can be a good therapy option
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for pregnant women suffering from symptoms of significant hyperacidity and
GERD The number of patients was a limiting factor and more studies need to be
done to establish the therapeutic benefits of combination antacids in pregnant
population.
GASTROINTESTINAL DISORDERS - Cost Studies
PGI6
A BUDGET IMPACT ANALYSIS TO ESTIMATE THE ECONOMIC IMPACT OF
LACTEST FOR THE DIAGNOSIS OF HYPOLACTASIA IN SPAIN
Darba J1, Kaskens L2, Ramírez de Arellano A3
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Barcelona, Spain
OBJECTIVES:To assess the economic impact of introducing LacTest®, a new drug
test which determines the level of hypolactasia in adults and elderly with clin-
ical symptoms of lactose intolerance on the Spanish market. METHODS: A bud-
get impact model was developed using the perspective of the Spanish National
Health System (NHS) with a 4-year time horizon. The model was populated with
data on diagnostic tests for hypolactasia, health care resource utilization, unit
costs and market shares. The potential number of diagnostic tests annually
performed in Spanish hospitals was based on a study estimating the number of
patients with clinical symptoms eligible for a diagnostic test among 45 Spanish
hospitals in Spain. Diagnostic tests included in this study were the hydrogen
breath test plus measurements of capillary blood glucose after an overload of
lactose, intestinal biopsy, fecal pH test, genetic testing and LacTest®. Costs
considered were diagnostic tests, laboratory tests, physician visits and time of
health care personnel. All costs referred to EUR 2012, using a 3% annual discount
rate. Direct medical annual costs per patient with each diagnostic test were
estimated before and after the introduction of LacTest®in order to estimate the
total annual health care costs. RESULTS: The Spanish population with clinical
symptoms of hypolactasia eligible for a diagnostic test was estimated to be
constant at 126,420 during the next four years. Total health care costs were
estimated at €81.7 million without the introduction of LacTest® and at €89.7
million after its introduction. CONCLUSIONS: The introduction of LacTest® only
shows a moderate increase in the total costs for the Spanish NHS. LacTest®
though is a test with a high reliability which decreases the need for repeating
the test and the cause for additional costs as is the case with some of the other
diagnostic tests compared in this study.
PGI7
ADHERENCE TO 5-AMINOSALICYLIC ACID (5-ASA) THERAPIES IN ULCERATIVE
COLITIS (UC): A UK BUDGET IMPACT ANALYSIS
Szende A1, Neves D2, McDermott JD2, Yen L3
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OBJECTIVES: Adherence with 5-aminosalicylic acid (5-ASA) treatments has
been shown to be associated with a reduction in disease relapses in UC patients.
The aim of this budget impact analysis was to explore and quantify how adher-
ence with individual 5-ASA treatments may impact direct medical costs,
through prevented relapses, in the UK. METHODS: A 1-year decision analytic
budget impact model was developed to combine data from a UK-based adher-
ence study of 5-ASA treatments with a chart review study on UC costs by relapse
status in the UK. The model calculates the rates of disease relapses, remissions,
and associated costs, based on adherence rates of each 5-ASA medication. The
model also allows running simulations of relative changes in treatment utiliza-
tion to show the associated budget impact from the perspective of the National
Health Service (NHS). RESULTS: Higher adherence rates (48.3% for MMX
Multi-Matrix System® [MMX] mesalamine; 40.7% for delayed release mesala-
mine [DRM] 800mg; 36.7% for modified release mesalamine [MRM]; 31.8% for
controlled release mesalamine [CRM] 1000mg; 29.7% for controlled release me-
salamine [CRM] 500mg; 29.6% for delayed release mesalamine [DRM] 400mg;
27.8% for balsalazide) were associated with lower hospitalization rates (6.6%;
7.3%; 7.7%; 8.1%; 8.3%; 8.3%; and 8.5%, respectively), lower annual hospitaliza-
tion costs (£330; £365; £383; £404; £414; £414; and £422, respectively), and
lower other medical costs, excluding 5-ASAs (£282; £292; £298; £305; £307; £308;
and £310, respectively). The model showed that a hypothetical move from the
current utilization mix of 5-ASA treatments to the 5-ASA with the highest ad-
herence rate could save the NHS approximately £92,800 annually per
1,000 UC patients. CONCLUSIONS: As non-adherence in UC is associated with
costly medical resource utilization, significant cost-offsets could be achieved
within the NHS by favoring the 5-ASA treatment with the highest adherence
rate.
PGI8
SECOND AND THIRD GENERATION FVIII TREATMENT RESOURCES
CONSUMPTION BREAK-EVEN POINT: THE PASS STUDY RESULTS
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OBJECTIVES: Inhibitor development is one of the most important and expensive
adverse event in patients with severe hemophilia A. A different incidence be-
tween second or third generation FVIII determine different resource consump-
tion in long term therapy. The Pass study aimed to assess the break-even point
in patients treated with ADVATE® or with another second or third generation
(FVIII X), considering effects on direct medical cost attributable to different
inhibitors development. METHODS: A model based on Oldenburg 2010 study
population characteristic( 348 Pre Treated Patients; FVIII 2%; no previous in-
hibitor stories) was developed comparing costs generate from ADAVATE® treat-
ment vs “FVIII X”. We considered a time horizon of 5 years and the National
Health System’s (NHS) point of view. In order to assess the validity of the break-
even point estimate, a sensitivity analysis was conducted modifying the per-
centages of patients allocated to prophylaxis or on demand regimen. RESULTS:
According to model results the overall cost during 5 years was: 243,966,787.44€
for ADAVATE® treatment and 223,402,102.06€ for “FVIII X” treatment. To gain
the break-even point between ADAVATE® and “FVIII X”, the number of patients
who should develop inhibitors was 4.98(1.43%) in 5 years. If all patients were
allocated to prophylaxis regimen, to gain the break-even point the number of
patients who should develop inhibitors was 9.68(2.78%). On the other hand for
on demand treatment it should be 1.29(0.37%). CONCLUSIONS: Considering the
high cost generated by inhibitor development and the lack of direct comparing
studies in scientific literature, the Pass Study provided interesting information
for decision makers in order to manage properly patients care. Inhibitor devel-
opment should be more considered during decision process, as an expensive
adverse event in hemophilic A patients treatment. A direct comparing study is
necessary to obtain more consistent results.
PGI9
PHARMACOECONOMIC EVALUATION OF ANTYHELICOBACTER THERAPY OF
ULCERS DUODENUM IN UKRAINE
Iakovlieva L1, Gerasymova O1, Mishchenko O1, Bezditko N2, Kyrychenko O3
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OBJECTIVES: Sequential antyhelicobacter therapy (A) is one of the ways to over-
come Helicobacter pylori (H. pylori) resistance to antibiotics. The aim is com-
pare the cost effectiveness ratio of different schemes of AT of first line: a
sequential therapy (scheme 1) and traditional triple therapy (scheme 2).
METHODS: Cost-effectiveness analysis was used. The schemes and their effi-
cacy were taken from a clinical study which were conducted in a hospital in
Kharkiv (Babak O.J., 2009). This trial involved 63 patients with peptic ulcers of
the duodenum (PUD) associated with H. pylori. Scheme 1: the drugs were pre-
scribed in 2 stages: the first (5 days) - rabeprazole (daily dose (DD) 40 mg),
amoxicillin (DD 2000 mg), the second (5 days) – rabeprazole (DD 40 mg), clari-
thromycin (DD 1000 mg) and bismuthate tripotassium dicitrate (DD 480 mg).
Scheme 2 included of rabeprazole (DD 40 mg), amoxicillin (DD 2000 mg), clari-
thromycin (DD 1000 mg) for 10 days. After administration of both schemes,
the patients received rabeprazole (DD 20 mg) for one month. A criterion of
efficacy was the number of patients (%) with H. pylori eradication: scheme 1 –
96.80%, scheme 2 – 72.00%. For determining the costs of the course of AT per
patient only the costs of the drugs were taken into account. The prices of drugs
were taken from the information system Drugs of Company Morion (Febru-
ary, 2012). The currency ratio of UAH to dollar (USA) on 01.02.12 was 7.98:1.
RESULTS: The costs for the scheme 1 are 170.28 $, for scheme 2 are 202.29$. The
first scheme (ÑER 175.91$) 1.6 times is more cost effective than the scheme 2
(ÑER 280.96$). CONCLUSIONS: The application of sequential antyhelicobacter
therapy can provide effective and economically founded AT PUD in medical
practice.
PGI12
COST OF DISEASE RELATED MALNUTRITION IN CROATIA – A HIDDEN COST IN
THE HEALTH CARE CLOSET WANTS OUT
Benkovic V1, Kolcic I2, Ivicevic Uhernik I1, Krznaric Z3, Vranesic Bender D3, Stevanovic R1
1Croatian Society for Pharmacoeconomics and Health Economics, Zagreb, Croatia, 2Faculty of
Medicine, University of Split, Split, Croatia, 3Centre for Clinical Nutrition, University Hospital
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OBJECTIVES: Disease related malnutrition (DRM) and its risk are still highly prev-
alent in some patient populations, depending on patients’ diagnoses and age, set-
ting and assessment tools used. DRM is associated with increased morbidity and
mortality, decreased QOL, frequent hospitalizations and increased health care
costs. Moreover, the economic and human costs of malnutrition are avoidable. The
purpose of the study is to estimate cost of DRM in Croatia by assessing direct costs
related to hospitalizations, drug consumption, outpatient care in selected illnesses
(IBD, gastric and lung cancers, chronic renal impairment and COPB). Selection was
based on most evidential relations and available data. Secondary objective was to
calculate and compare the total and per capita medical expenditures for people
with DRM and identify cost saving potential. METHODS: Prevalence-based cost-of-
illness methodology was used to estimate the direct costs (hospital, drugs, physi-
cian and institutional care) and indirect costs (sickness leave) associated with dis-
ease complications related to DRM, as well as patient monitoring and drugs. The
analysis was oriented primary to adult patients receiving hospital in-patient, out-
patient or specified community health-care services. RESULTS: The annual cost
associated with adult malnourished patients in selected illnesses is estimated at
over 100€ million. Most of this cost are in acute hospital (infections, rehospitaliza-
tions) and home care with nutrition support estimated to 10 % of spend. This
cost is substantial, inclining to rise with population aging (older people have in-
creased DRM risk). So far there has been no attention focused on the economic
burden associated with DRM in Croatia or the potential for savings arising from
improved detection and treatment of those at risk. CONCLUSIONS: Screening of
malnutrition as well as better nourishing therapies, in sense of better adherence to
guidelines, would not only evade mortality and morbidity, but save substantial
resources.
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